Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis

General Pharmacology

Volumn 29, Issue 2, 1997, Pages 181-196

  Windmeier, C ^a   Gressner, A M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Hepatic fibrogenesis; Hepatic stellate cells; Pentoxifylline; Pharmacology

Indexed keywords

BUCLADESINE; CYCLIC AMP; CYTOKINE; DIBUTYRYL CYCLIC GMP; FORSKOLIN; GROWTH FACTOR; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; THEOBROMINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CELL CULTURE; DRUG MECHANISM; DRUG METABOLISM; ENDOTOXEMIA; ENZYME INHIBITION; ERYTHROCYTE DEFORMABILITY; FIBROBLAST; FIBROGENESIS; FIBROSIS; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MICROCIRCULATION; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SKIN TOXICITY; STELLATE CELL; THROMBOCYTE AGGREGATION; TISSUE OXYGENATION;

ANIMALS; HUMANS; LIVER CIRRHOSIS; PENTOXIFYLLINE; VASODILATOR AGENTS;

EID: 0030858931     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00314-X     Document Type: Review

References (194)

1. Accetto B. (1982) Beneficial hemorrheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator nylidrin. Am. Heart J. 103, 864-869.
2. Alegre M. L., Gastaldello K., Abramowicz D., Kinnaert P., Vereerstraeten P., DePauw L., Vandenabeele P., Moser M., Leo O. and Goldman M. (1991) Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52, 674-679.
3. Alt M. and Caselmann W. H. (1995) Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. J. Hepatol. 23, 746-758.
4. Ambrus J. L., Stadler S. and Kulaylat M. (1995) Hemorrheologic effects of metabolites of pentoxifylline (Trental). J. Med. 26, 65-75.
5. 2-macroglobulin gene. Eur. J. Biochem. 168, 641-646.
6. Anthony P. P., Ishak K. G., Nayak N. C., Pousen H. E., Scheuer P. J. and Sobin L. H. (1978) The morphology of cirrhosis. J. Clin. Pathol. 31, 395-414.
7. Arenson D. M., Friedman S. L. and Bissel D. M. (1988) Formation of extracellular matrix in normal rat liver: lipocytes as a major source of proteoglycan. Gastroenterology 95, 441-447.
8. Attal M., Huguet F., Rubie H., Charlet J. P., Schlaifer D., Huynh A., Laurent G. and Pris J. (1993) Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82, 732-736.
9. Aviado D. M. and Dettelbach H. R. (1984) Pharmacology of pentoxifylline: a hemorrheologic agent for the treatment of intermittent claudication. Angiology 35, 407-417.
10. Aviado D. M. and Porter J. M. (1984) Pentoxifylline: a new drug for the treatment of intermittent claudication. Pharmacotherapy 4, 297-307.
11. Bachem M. G., Melchior R. and Gressner A. M. (1989a) The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J. Clin. Chem. Clin. Biochem. 27, 555-565.
12. Bachem M. G., Riess U. and Gressner A. M. (1989b) Liver fat storing cell proliferation is stimulated by epidermal growth factor/transforming growth factor alpha and inhibited by transforming growth factor beta. Biochem. Biophys. Res. Commun. 162, 708-714.
13. 1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. Virchoff's Arch. B. Cell Pathol. 63, 123-130.
14. Bachmann S., Caldwell-Kenkel J. C., Currin R. T., Tanaka Y., Takei Y., Marzi I., Thurman R. G. and Lemasters J. J. (1993) Ultrastructural correlates of liver graft failure from storage injury: studies of graft protection by Carolina rinse solution and pentoxifylline. Transplant. Proc. 25, 1620-1624.
15. Baeuerle P. A. (1991) The inducible transcription factor NF-κB: regulation by distinct protein subunits. Biochim. Biophys. Acta 1072, 63-80.
16. Balazs C. and Kiss E. (1994) Immunological aspects of the effect of pentoxifylline (trental). Acta Microbiol. Immunol Hung. 41, 121-126.
17. Barosso-Aranda J. and Schmid-Schönbein G. W. (1990) Pentoxifylline pretreatment decreases the pool of circulating activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock. Biorheology 27, 401-418.
18. Beelen D. W., Sayer H. G., Franke M., Scheulen M. E., Quabeck K., Mohnke M., Oidtmann M. and Schaefer U. W. (1993) Constant intravenous pentoxifylline infusions in allogenic marrow transplant recipients: results of a dose escalation study. Bone Marrow Transpl. 12, 363-370.
19. Beermann B. Ings R., Mansby J., Chamberlain J. and McDonald A. (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin. Pharmacol. Ther. 37, 25-28.
20. 2 analog reduces rat hepatic and ito cell collagen gene expression and collagen accumulation after bile duct ligation injury. Hepatology 17, 707-714.
21. Berkenboom G., Unger P., Goldman M., Fang Z. Y. and Fontaine J. (1991) Prevention of cyclosporine A-induced vascular toxicity by pentoxifylline. J. Cardiovasc. Pharmacol. 18, 761-768.
22. Berman B. and Duncan M. R. (1989) Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J. Invest. Dermatol. 82, 605-610.
23. Berman B. and Duncan M. R. (1990) Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br. J. Dermatol. 123, 339-346.
24. Berman B., Wietzerbin J., Sanceau J., Merlin G. and Duncan M. R. (1992) Pentoxifylline inhibits certain constitutive and tumor necrosis factor-α-induced activities of human normal dermal fibroblasts. J. Invest. Dermatol. 98, 706-712.
25. Bessler H., Gilgal R., Djaldetti M. and Zahavi I. (1986) Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J. Leukocyte Biol. 40, 747-754.
26. Bianco J. A., Applebaum F. R., Nemunaitis J., Almgren J., Andrews F., Kettner P., Shields A. and Singer J. W. (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78, 1205-1211.
27. Bissel D. M., Wang S. S., Jarnagin W. R. and Roll F. J. (1995) Cell-specific expression of transforming growth factor-beta in rat liver - Evidence for autocrine regulation of hepatocyte proliferation. J. Clin. Invest. 96, 447-455.
28. Biswas D. K., Dezube B. J., Ahlers C. M. and Pardee A. B. (1993) Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action. J. AIDS 6, 778-786.
29. Blomhoff R. and Wake K. (1991) Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J. 5, 271-277.
30. Boigk G., Raetsch C., Stoeter L., Waldschmidt J., Herbst H., Riecken E. O. and Schuppan D. (1995) Antifibrotic effect of pentoxiphylline in rat biliary fibrosis due to bile duct obstruction. J. Hepatol. 23(suppl 1), 142.
31. Border W. A., Noble N. A., Yamomoto T., Harper J. R., Yamaguchi Y., Pierschbacher M. D. and Ruoslahti E. (1992) Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360, 361-364.
32. Breuille D., Farge M. C., Rose F., Arnal M., Attaix D. and Obled C. (1993) Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am. J. Physiol. 265, E660-666.
33. Brunner, L. J., Vadiei K., Iyer L. V. and Luke D. R. (1989) Prevention of cyclosporine-induced nephrotixicity with pentoxifylline. Ren. Fail. 11, 97-104.
34. Bruns R. F. (1981) Adenosine antogonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. 30, 325-333.
35. Bryce T. A. and Burrows J. L. (1980) Determination of oxpentifylline and a metabolite, 1-(5′-hydroxyhexyl)-3,7-dimethylxanthine, by gas-liquid chromatography using a nitrogen-selective detector. J. Chromatogr 181, 355-361.
36. 1 - comparison with fibronectin. Biochem. Biophys. Res. Commun. 199, 1019-1026.
37. Chang C. C., Wu Y. C., Chiu H. C., Liu Y. L. and Lu Y. C. (1991) Pentoxifylline inhibits the proliferation of human fibroblasts derived from normal, hypertrophic scar and keloid skin and their mitochondrial activity and collagen synthesis. Eur. J. Dermatol. 1, 214-220.
38. Chang C. C., Chang T. C., Kao S. C. S., Kuo Y. F. and Chien L. F. (1993) Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol. 129, 322-327.
39. Chao C. C., Hu S., Sheng W. S., Tsang M. and Peterson P. K. (1995) Tumor necrosis factor-alpha mediates the releast of bioactive transforming growth factor-beta in murine microglial cell cultures. Clin. Immunol. Immunopathol. 77, 358-365.
40. Chazouilleres O., Ballet F., Chretien Y., Marteau P., Rey C., Maillard D. and Poupon R. (1989) Protective effect of vasodilators on liver function after long hypothermic preservation: a study in the isolated perfused rat liver. Hepatology 9, 824-829.
41. Chen W., Steffan A. M., Braunwald J., Nonnenmacher H., Kirn A. and Gendrault J. L. (1990) Inhibition in fat storing cell multiplication by a factor produced by normal cultured murine hepatocytes. J. Hepatol. 11, 330-338.
42. Chojkier M. and Brenner D. A. (1988) Therapeutic strategies for hepatic fibrosis. Hepatology 8, 176-182.
43. Chunfang G., Gressner G., Zoremba M. and Gressner A. M. (1996) Transforming growth factor-beta (TGF-beta) expression in isolated and cultured rat hepatocytes. J. Cell Physiol. 167, 394-405.
44. Cleary J. D., Chapman S. W. and Nolan R. L. (1992) Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36, 977-981.
45. Coccia M. T., Waxman K., Soliman M. H., Tominaga G. and Pinderski L. (1989) Pentoxifylline improves survival following haemorrhagic shock. Crit. Care Med. 17, 36-41.
46. Confer D. L. and Eaton J. W. (1982) Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 217, 948-950.
47. Currie M. S., Rao K. M. K., Padmanabhan J., Jones A., Crawford J. and Cohen H. J. (1990) Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression degranulation, and superoxide production. J. Leukocyte Biol. 47, 244-250.
48. Currin R. T., Reinstein L. J., Lichtman S. N., Thurman R. G. and Lemasters J. J. (1993) Inhibition of tumor necrosis factor release from cultured rat Kupffer cells by agents that reduce graft failure from storage injury. Transplant Proc. 25, 1631-1632.
49. Czaja M. J., Xu J. and Alt E. (1995) Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 108, 1849-1854.
50. DeVault G. A., Kohan D. E., Nelson E. W. and Holman J. M. (1994) The effects of oral pentoxifylline on the cytokine release syndome during inductive OKT3. Transplantation 57, 532-540.
51. Dezube B. J., Sherman M. L., Fridovich-Keil J. L., Allen-Ryan J. and Pardee A. B. (1993) Downregulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol. Immunother. 36, 57-60.
52. Doherty G. M., Jensen J. C., Alexander N. R., Buresh C. M. and Norton J. A. (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110, 192-198.
53. Duncan M. R., Hasan A. and Berman B. (1995) Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J. Invest. Dermatol. 104, 282-286.
54. Edwards M. J., Abney D. L. and Miller F. N. (1991) Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. Surgery 110, 199-204.
55. Edwards M. J., Heniford B. T., Klar E. A., Doak K. W. and Miller F. N. (1992) Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J. Clin. Invest. 90, 637-641.
56. Endres S., Fülle H. J., Sinha B., Stoll D., Dinarello C. A., Gerzer R. and Weber P. C. (1991) Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor-α and interleukin-1β by human mononuclear cell. Immunology 72, 56-60.
57. Eyken Van P., Geerts A., De Bleser P., Lazou J. M., Vrijsen R., Scoit R., Wisse E. and Desmet V. J. (1992) Localization and cellular source of extracellular matrix protein tenascin in normal and fibrotic rat liver. Hepatology 15, 909-916.
58. Fazely F., Dezube B. J., Allen-Ryan J. A., Pardee A. B. and Ruprecht R. M. (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type I in human peripheral blood mononuclear cells and in cultured T cells. Blood 77, 1653-1656.
59. Flynn W. J., Cryer H. G. and Garrison R. N. (1991) Pentoxifylline but not saralasin restores hepatic blood flow after resuscitation from hemorrhagic shock. J. Surg. Res. 50, 616-621.
60. Friedman S. L., Roll F. J., Boyles J. and Bissell D. M. (1985) Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc. Natl. Acad. Sci. USA. 82, 8681-8685.
61. Friedman S. L. (1990a) Cellular sources of collagen and regulation of collagen production in liver. Sem. Liver Dis. 10, 20-29.
62. Friedman S. L. (1990b) Acetaldehyde and alcoholic fibrogenesis: fuel to the fire, but not the spark. Hepatology 12, 609-612.
63. Friedman S. L. (1993) The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328, 1828-1835.
64. Funk J. O., Ernst M., Schönharting M. M. and Zabel P. (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int. J. Immunopharmacol. 17, 1007-1016.
65. Gastpar H., Ambrus J. L., Ambrus C. M., Spavento P., Wever F. J. and Thurber L. E. (1977) Study of platelet aggregation in vivo. III. Effect of pentoxifylline. J. Med. 8, 191-197.
66. Geerts A., Schellinck L., Bouwens L. and Wisse E. (1988) Cell population kinetics of Kupffer cells during the onset of fibrosis in rat liver by chronic carbon tetrachloride administration. J. Hepatol. 6, 50-56.
67. Geerts A., Lazou J. M., De Bleser P. and Wisse E. (1991) Tissue distribution, quantitation and proliferation kinetics of fat storing cells in carbon tetrachloride-injured rat liver. Hepatology 13, 1193-1202.
68. Glaser V. (1996) Gene transfer to the liver. Molec. Med. Today 2, 47.
69. Goldberg R. M., Loprinzi C. L., Mailliard J. A., O'Fallon J. R., Krook J. E., Ghosh C., Hesteroff R. D., Chong S. F., Reuter N. F. and Shanahan T. B. (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double blind, placebo-controlled trial. J. Clin. Oncol. 13, 2856-2859.
70. Gottlöber P., Krähn G., Korting H. C., Stock W. and Peter R. U. (1996) Treatment of cutaneous radiation fibrosis with pentoxifylline and vitamin E. A case report. Strahlenther Onkol 172, 34-38.
71. Gressner A. M. and Haarmann R. (1988) Hyaluronic acid synthesis and secretion by rat liver fat storing cells (perisinusoidal lipocytes) in culture. Biochem. Biophys. Res. Commun. 151, 222-229.
72. Gressner A. M. and Bachem M. G. (1990) Cellular sources of noncollagenous matrix proteins: role of fat storing cells in fibrogenesis. Sem. Liver Dis. 10, 30-46.
73. Gressner A. M. (1991) Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur. J. Clin. Chem. Clin. Biochem. 29, 293-311.
74. Gressner A. M. and Lahme B. (1991) Inhibitory actions of hepatocyte plasma membranes on proliferation, protein-and proteoglycan synthesis of cultured rat fat storing cells. In Cells of the Hepatic Sinusoid. Vol 3, (Edited by Wisse E., Knook D. L., McCuskey R. S.) The Kupffer Cell Foundation, Leiden, The Netherlands, pp. 237-241.
75. Gressner A. M., Lotfi S., Gressner G. and Lahme B. (1992) Identification and partial characterization of a hepatocyte-derived factor promoting proliferation of cultured fat storing cells (parasinusoidal lipocytes). Hepatology 16, 1250-1266.
76. Gressner A. M. and Bachem M. G. (1994) Cellular communications and cell-matrix interactions in the pathogenesis of fibroproliferative disease: liver fibrosis as a paradigm. Ann. Biol. Clin. 52, 205-226.
77. Gressner A. M. (1994a) Perisinusoidal lipocytes and fibrogenesis. Gut 35, 1331-1333.
78. Gressner A. M. (1994b) Activation of proteoglycan synthesis in injured liver - a brief review of molecular and cellular aspects. Eur. J. Clin. Chem. Clin. Biochem. 32, 225-237.
79. Gressner A. M. and Lahme B. (1995) Treatment of rat hepatocytes with transforming growth factor-beta1 increases their mitogenic activity for cultured fat storing cells. Inter. Hepatol. Commun. 4, 94-101.
80. Gressner A. M. and Bachem, M. G. (1995) Molecular mechanisms of liver fibrogenesis - a homage to the role of activated fat-storing cells. Digestion 56, 335-346.
81. Gressner A. M., Polzar B., Lahme G. and Mannherz H. G. (1996) Induction of rat liver parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor beta. Hepatology 23, 571-581.
82. Grigoleit H. G. and Jacobi G. (1977) Microrheological effects of the vasoactive compound 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (Pentoxifylline, BL 191). Vasa 6, 274-278.
83. Guido M., Rugge M., Chemello L., Leandro G., Fattovich G., Giustina G., Cassaro M. and Alberti A., (1996) Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J. Hepatol. 24, 301-307.
84. Hammerschmidt D. E., Kotasek D., McCarthy T., Huh P. W., Freyburger G. and Vercellotti G. M. (1988) Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J. Lab Clin. Med. 112, 254-263.
85. Hendriks H. F. J., Brouwer A. and Knook D. L. (1987) The role of hepatic fat storing (stellate) cells in retinoid metabolism. Hepatology 7, 1368-1371.
86. Hinze H. J. (1972) The pharmacokinetics of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191) in man. Arzneimittelforschung 22, 1492-1495.
87. Hinze H. J., Grigoleit H. G. and Rethy B. (1976) Bioavailability and pharmacokinetics of pentoxifylline and Trental 400 in man. Pharmatherapeutica I, 160-171.
88. Hoffmann C., Lahme B., Brenzel A. and Gressner A. M. (1994) The relation between hepatocellular damage and activation of fat storing cell proliferation in vitro. Inter. Hepatol. Commun. 2, 29-36.
89. Housset C., Rockey D. C. and Bissell D. M. (1993) Endothelin receptors in rat liver - lipocytes as a contractile target for endothelin-1. Proc. Natl. Acad. Sci. USA. 90, 9266-9270.
90. Ikossi M. G., Ambrus J. L. and Chadha K. C. (1986) Regulation of in vitro human leukocyte interferon production: effect of prostaglandin synthetase and phosphodiesterase inhibition. Res. Commun. Chem. Pathol. Pharmacol. 54, 379-393.
91. Ings R. M. J., Nüdemberg G., Burrows J. L. and Bryce T. A. (1982) The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. Eur. J. Clin. Pharmacol. 23, 539-543.
92. Isaka Y., Brees D. K., Ikegaya K., Kaneda Y., Imai E., Noble N. A. and Border W. A. (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2, 418-423.
93. Isbrucker R. A. and Peterson T. C. (1995) Effect of PDGF, pentoxifylline and metabolite-1 on collagen production in porcine hepatic stellate cells. Hepatology 22, 280A.
94. Ishizaka A., Wu Z., Stephens K. E., Harada H., Hogue R. S., O'Hanley P. T. and Raffin T. A. (1988) Attenuation of acute lung injury in septic guinea-pig by pentoxifylline. Am. Rev. Respir. Dis. 138, 376-382.
95. Jarrett P. E. M., Moreland M. and Browse N. L. (1977) The effect of oxpentifylline on fibrinolytic activity and plasma fibrinogen levels. Curr. Med. Res. Opin. 4, 492-495.
96. Kawada N. and Inoue M. (1994) Effect of adrenomedullin on hepatic pericytes (stellate cells) of the rat. FEBS Lett. 356, 109-113.
97. Kawada N., Kobayashi K. and Inoue M. (1995) Inhibition of myofibroblastic transformation of stellate cells by methylxanthines. Hepatology 22, 285A.
98. Kawada N., Kuroki T., Kobayashi K., Inoue M. and Kaneda K. (1996) Inhibition of myofibroblastic transformation of cultured rat hepatic stellate cells by methylxanthines and dibutyryl cAMP. Dig. Dis. Sci. 41, 1022-1029.
99. Katsunuma H., Imamura T. and Ishigaki Y. (1982) The clinical efficacy of Trental against various types of cerebrovascular disease. J. New Remedies Clin. 31, 1845-1851.
100. Khanna A., Li B. G., Li P. X. and Suthanthiran M. (1996) Transforming growth factor-beta(1): regulation with a TGF-beta(1) antisense oligomer. Kidney Int. 49, S2-S6.
101. 198Au-colloid-scintigraphy. Med Klin. 74, 1254-1256.
102. Kozaki K., Egawa H., Bermudez L., Feduska N. J., So S. and Esquivel C. O. (1993) Pentoxifylline inhibits production of superoxide anion and tumor necrosis factor by Kupffer cells in rat liver preservation. Transplant Proc 25, 3025-3026.
103. Kozaki K., Egawa H., Bermudez L., Keefe E. B., So S. K. and Esquivel C. O. (1995) Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation. Hepatology 21, 1079-1082.
104. LaMarre Y., Wollenberg G. K., Gonias S. L. and Hayes M. A. (1991) Biology of disease: cytokine binding and cleaning properties of proteinase-activated alpha2-macroglobulins. Lab. Invent. 65, 3-14.
105. Leonhardt H. and Grigoleit H. G. (1977) Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn-Schmiedeberg's Arch. Pharmacol. 299, 197-200.
106. Maher J. J. and Tzagarakis C. (1994) Partial cloning of the M subunit of laminin from adult rat lipocytes: expression of the M subunit by cells isolated from normal and injured liver. Hepatology 19, 764-770.
107. B-and a cyclic AMP-mediated pathway. J. Cardiovasc. Pharmacol. 26, S132-S134.
108. Mancini R., Benedetti A. and Jezequel A. M. (1994) An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat. Virchows Archiv. 424, 25-31.
109. Mandi Y., Farkas G. and Ocsovszky I. (1995) Effects of pentoxifylline and PentaglobinO on TNF and IL-6 production in septic patients. Acta. Microbiol. Immunol. Hung. 42, 301-308.
110. Marteau P., Ballet F., Chazouilleres O., Chretien Y., Rey C., Petit D. and Poupon R. (1989) Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology 9, 820-823.
111. 2) by pentoxifylline from human vascular tissue. Drug Res. 32, 1315-1318.
112. Meyer D. H., Krull N., Dreher K. L. and Gressner A. M. (1992) Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors. Hepatology 16, 204-216.
113. Milani S., Herbst H., Schuppan D., Stein H. and Surrenti C. (1991) Transforming growth factors-beta1 and -beta2 are differentially expressed in fibrotic liver disease. Am. J. Pathol. 139, 1221-1229.
114. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A. and Kaplan G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680.
115. Mohler W., Bletz I. and Reiser M. (1966) Die Struktur von Ausscheidungsprodukten des 1-Hexyl-3,7-dimethylxanthins. 1. Über den Metabolismus des 1-Hexyl-3,7-dimethylxanthins. Arch. Pharm. 299, 448-456.
116. Müller R. (1981) Hemorheology and peripheral vascular diseases: a new therapeutic approach. J. Med. 12, 209-235.
117. Müller R. and Lehrach F. (1981) Haemorheology and cerebrovascular disease: multi-functional approach with pentoxifylline. Curr. Med. Res. Opin. 7, 253-263.
118. Noel P. S., Nelson S., Bokulic R., Bagby G., Lippton H., Lipscomb B. and Summer W. (1990) Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 47, 1023-1029.
119. Ogawa K., Suzuki J. I., Narasaki M. and Mori M. (1985) Healing of focal injury in the rat liver. Am. J. Pathol. 119, 158-167.
120. Palladino M. A., Morris R. E., Starnes H. F. and Levinson A. D. (1990) The transforming growth factor-betas: a new family of immunoregulatory molecules. Ann. NY Acad. Sci. USA 593, 181-187.
121. Park B. H., Good R. A., Beck N. P. and Davis B. B. (1971) Concentration of cyclic adenosine 3′,5′-monophosphate in human leucocytes during phagocytosis. Nature 229, 27-29.
122. Peng X. X., Currin R. T., Thurman R. G. and Lemasters J. J. (1995) Protection by pentoxifylline against normothermic liver ischemia/reperfusion in rats. Transplantation 59, 1537-1541.
123. Peterson T. C. and Isbrucker R. A. (1992) Fibroproliferation in liver disease: role of monocyte factors. Hepatology 15, 191-197.
124. Peterson T. C. (1993) Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 17, 486-493.
125. Peterson T. C., Isbrucker R. A. and Hooper M. L. (1994) In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antogonists. Immunopharmacology 28, 259-270.
126. Peterson T. C. and White B. (1995) Role of adenosine receptors in the inhibition of fibroproliferation due to pentoxifylline and M-1 metabolite. Hepatology 22, 475A.
127. Peterson T. C. and Neumeister M. (1995) Fibroproliferation in swine and rat models: effect of pentoxifylline. Hepatology 22, 474A.
128. Pietrzkowski Z., Wernicke D., Porcu P., Jameson B. A. and Baserga R. (1992) Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 52, 6447-6451.
129. Pilette C., Rifflet H., Haiga M., Moreau A., Gallois Y., Girault A., Le Jeune J. J., Feldmann G. and Cales P. (1995) Effects of simvastatin, pentoxifylline, and spironolactone on hepatic fibrosis and portal hypertension in bile duct ligated rats. Hepatology 22, 466A.
130. Pinzani M. (1995a) Novel insights into the biology and physiology of the Ito cell. Pharmacol. Ther. 66, 387-412.
131. Pinzani M. (1995b) Hepatic stellate (Ito) cells: expanding roles for a liver-specific pericyte. J. Hepatol. 22, 700-706.
132. Pinzani M., DeFranco R., Caligiuri A., Gentilini A., Casini A., Carloni V., Marra F., Romanelli R. G. and Gentilini P. (1995) Cellular basis for the use of pentoxifylline (PTX) as a potential antifibrogenic agent. J. Hepatol. 23(suppl 1), 81.
133. Pinzani M., Milani S., Defranco R., Grappone C., Caligiuri A., Gentilini A., Tostiguerra C., Maggi M., Failli P., Ruocco C. et al. (1996) Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110, 534-548.
134. Popper H., Davidson C. S., Leevy C. M. and Schaffner F. (1969) The social impact of liver disease. N. Engl. J. Med. 281, 1455-1458.
135. Porter J. M., Cutler B. C., Lee B. Y., Reich T. and Reichle F. A. (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. 104, 66-77.
136. Preaux A. M., Mallat A., Dhumeaux D. and Mavier P. (1995) Pentoxifylline inhibits the proliferation and the fibrogenic properties of human hepatic myofibroblastic cells. Hepatology 22, 280A.
137. Raetsch C., Boigk G., Stroeter L., Waldschmidt J., Herbst H., Riecken E. O. and Schuppan D. (1996) Pentoxifyllin hemmt die Kollagenablagerung bei der frühen, nicht aber bei der fortgeschrittenen biliären Leberfibrose der Ratte. Z. Gastroenterol. 34, 50.
138. Rall T. W. (1982) Evolution of the mechanism of action of methylxanthines: from calcium mobilizers to antagonists of adenosine receptors. Pharmacologist 24, 277-287.
139. Rames A., Poirier J. M., LeCoz F., Midavaine M., Lecocq B., Grange J. D., Poupon R., Cheymol G. and Jaillon P. (1990) Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin. Pharmacol. Ther. 47, 354-359.
140. Ramadori G., Veit T., Schwögler S., Dienes H. P., Knittel T., Rieder H. and Meyer-zum-Büschenfelde K. H. (1990) Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat storing (Ito) cells. Virchows Arch. B Cell Pathol 59, 349-357.
141. Ramadori G. (1991) The stellate cell (Ito-cell, fat storing cell, lipocyte, perisinusoidal cell) of the liver. Virchows Arch. B Cell Pathol. 61, 147-158.
142. Ramadori G., Knittel T., Odenthal M., Schwögler S., Neubauer K. and Meyer-zum-Büschenfelde K. H. (1992) Synthesis of cellular fibronectin by rat liver fat storing (Ito) cells - regulation by cytokines. Gastroenterology 103, 1313-1321.
143. Rao K. M. K., Currie M. S., McCachren S. S. and Cohen H. J. (1991) Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol. 135, 314-325.
144. Reed W. R. and DeGowin R. L. (1992) Suppressive effects of pentoxifylline on natural killer cell activities. J. Lab. Clin. Med. 119, 763-771.
145. Rieder H., Meyer-zum-Büschenfelde K. H. and Ramadori G. (1992) Functional spectrum of sinusoidal endothelial liver cells. Filtration, endocytosis, synthetic capacities and intercellular communication. J. Hepatol. 15, 237-250.
146. Rieneck K., Diamant M., Haahr P. M., Schönharting M. and Bendtzen K. (1993) In vitro immunomodulatory effects of pentoxifylline. Immunol. Lett. 37, 131-138.
147. Rockey D. C. and Chung J. J. (1994) Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J. Invest Med. 42, 660-670.
148. Rockey D. C. and Chung J. J. (1995) Endothelin (ET) antagonism in experimental hepatic fibrosis: implications for endothelin in the pathogenesis of wound healing. Hepatology 22, 221A.
149. Rosenbaum J. and Blazejewski S. (1995) Regulation of Ito cell proliferation by soluble factors. J. Hepatol. 22, 65-70.
150. Ross R. (1989) Platelet-derived growth factor. Lancet 1, 1179-1182.
151. Schade U. F. (1989) The role of prostacyclin in the protective effects of pentoxifylline and other xanthine derivatives in endotxing action in mice. Eicosanoids 2, 183-188.
152. Schäfer S., Zerbe O. and Gressner A. M. (1987) The synthesis of proteoglycans in fat storing cells of rat liver. Hepatology 7, 680-687.
153. Schandene L., Vandenbussche P., Crusiaux A., Alegre M. L., Abramovicz D., Dupont E., Content J. and Goldman M. (1992) Differential effects of pentoxifylline on the production of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 76, 30-34.
154. Schmalzer E. A. and Chien C. L. (1984) Filterability of subpopulations of leukocytes: effect of pentoxifylline. Blood 64, 542-546.
155. Schröer R. H. (1985) Antithrombotic potential of pentoxifylline - a hemorheologically active drug. Angiology 36, 387-398.
156. Schwoegler S., Neubauer K., Knittel T., Chung A. E. and Ramadori G. (1994) Entactin gene expression in normal and fibrotic rat liver and in rat liver cells. Lab. Invest. 70, 525-536.
157. Semmler J., Gebert U., Eisenhut T., Moeller J., Schönharting M. M., Allera A. and Endres S. (1993) Xanthine derivatives: comparison between suppression of tumor necrosis factor-α production and inhibition of cAMP phosphodiesterase activity. Immunology 78, 520-525.
158. Shiratori Y., Takada H., Hikiba Y., Nakata R., Okano K., Domatsu Y., Niwa Y., Matsumura M., Shiina S., Omata M. et al. (1993) Production of chemotactic factor, interleukin-8, from hepatocytes exposed to ethanol. Hepatology 18, 1477-1482.
159. Sinha B., Semmler J., Eisenhut T., Eigler A. and Endres S. (1995) Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25, 147-153.
160. Smedsrod B., Debleser P. J., Braet F., Lovisetti P., Vanderkerken K., Wisse E. and Geerts A. (1994) Cell biology of liver endothelial and Kupffer cells. Gut 35, 1509-1516.
161. Smith R. V., Waller E. S., Doluisio J. T., Banzer M. T. and Puri S. K. (1986) Pharmacokinetics of orally administered pentoxifylline in humans. J. Pharmacol. Sci. 75, 47-52.
162. Stefanovich V., Jarvis P. and Grigoleit H. G. (1975) Effect of pentoxifylline on the cyclic AMP system in platelets. Med. Welt 26, 2230-2233.
163. Stefanovich V. (1975) Effect of pentoxifylline on energy rich phosphates in rat's erythrocytes. Res. Commun. Chem. Pathol. Pharmacol. 10, 747-750.
164. Sternitzky R. and Seige K. (1985) Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. Curr. Med. Res. Op. 9, 602-610.
165. Stricter R. M., Remick D. G., Ward P. A., Spengler R. N., Lynch J. P., Larrick J. and Kunkel S. L. (1988) Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155, 1230-1236.
166. Sullivan G. W., Carper H. T., Novick W. J. and Mandell G. L. (1988) Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect. Immunol. 56, 1722-1729.
167. Sullivan G. W., Linden J., Hewlett E. L., Carper H. T., Hylton J. B. and Mandell G. L. (1990) Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface. J. Immunol. 145, 1537-1544.
168. Taffet S. M., Singhel K. J., Overholtzer J. F. and Shurtleff S. A. (1989) Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol. 120, 291-300.
169. Tannenbaum C. S. and Hamilton T. A. (1989) Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol. 142, 1274.
170. Thiel M., Bardenheuer H., Pöch G., Madel C. and Peter K. (1991) Pentoxifylline does not act via adenosine receptors in the inhibiton of the superoxide anion production of human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 180, 53-58.
171. Tighe D., Moss R., Hynd J., Boghossian S., Al-Saady N., Heath M.F. and Bennett E. D. (1990) Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit. Care Med. 18, 184-189.
172. Tilg H., Eibl B., Pichl M., Gächter A., Herold M., Brankova J., Huber C. and Niederwieser D. (1993) Immune response modulation by pentoxifylline in vitro. Transplantation 56, 196-201.
173. Vasilev V. S. and Pronko N. V. (1990) Use of trental in combined treatment of viral hepatitis. Klin. Med. Mosk. 68, 68-70.
174. Verghese M. W., McConnell R. T., Strickland A. B., Gooding R. C., Stimpson S. A., Yarnall D. P., Taylor J. D. and Furdon P. J. (1995) Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272, 1313-1320.
175. Wang P., Ba Z. F., Morrison M. H., Ayala A. and Chaudry I. H. (1992) Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery 112, 451-458.
176. Ward A. and Clissold S. P. (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34, 50-97.
177. Weinberg J. B., Mason S. N. and Wortham T. S. (1992) Inhibition of tumore necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) messenger RNA (mRNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-α and IL-1β mRNA expression from acivicin-induced monocytoid differentiation. Blood 79, 3337-3343.
178. Weiner F. R., Giambrone M. A., Czaja M. J., Shah A., Annoni G., Takahashi S., Eghbali M. and Zern M. A. (1990) Ito-cell gene expression and collagen regulation. Hepatology 11, 111-117.
179. Weiner F. R., Blaner W. S., Szaja M. J., Shah A. and Geerts A. (1992) Ito cell expression of a nuclear retinoic acid receptor. Hepatology 15, 336-342.
180. Weithmann K. U. (1980) The influence of pentoxifylline on interaction between blood vessel wall and platelets. IRCS Med. Sci. 8, 293-294.
181. Weithmann K. U. (1983) Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP. Gen. Pharmacol. 14, 161-162.
182. Welsh C. H., Lien D., Worthen G. S. and Weil J. V. (1988) Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am. Rev. Respir. Dis. 138, 1106-1114.
183. Wenig H. G. and Koppenhagen K. (1981) Effects of pentoxifylline on cerebral and hepatic blood flow: scintigraphic measurements in patients with cerebrovascular insufficiency and liver diseases. In Disorders of Blood Flow: New Therapeutic Aspects. (Edited by Manrique and Müller) pp. 95-106. Excerpta Medica, Amsterdam.
184. Win K. M., Charlotte F., Mallat A., Cherqui D., Martin N., Mavier P., Preaux A. M., Dhumeaux D. and Rosenbaum J. (1993) Mitogenic effect of transforming growth factor-beta 1 on human Ito cells in culture: evidence for mediation by endogenous platelet-derived growth factor. Hepatology 18, 137-145.
185. Windmeier C. and Gressner A. M. (1994) Transformation into myofibroblasts sensitizes Ito-cells for the inhibitory effect of pentoxifylline. Eur. J. Cell Biol. 64(suppl 40), 64.
186. Windmeier C. and Gressner A. M. (1995) Antiproliferative Wirkung cAMP-steigernder Substanzen auf Myofibroblasten. Z. Gastroenterol. 33, 35.
187. Windmeier C. and Gressner A. M. (1996) Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts. Biochem. Pharmacol. 51, 577-584.
188. Wu J. and Danielsson A. (1994) Inhibition of hepatic fibrogenesis: a review of pharmacologic candidates. Scand. J. Gastroenterol. 29, 385-391.
189. Zabel P., Schönharting M. M., Wolter D. T. and Schade U. F. (1989) Oxpentifylline in endotoxaemia. Lancet 334, 1474-1477.
190. Zabel P., Leimenstoll G., Schröder P., Elfeldt R., Schlaak M. and Niedermayer W. (1991) Pentoxifylline suppresses OKT3-induced tumor necrosis factor-alpha formation in renal transplant recipients. Z. Transplantationsmed 3, 62-65.
191. Zabel P., Schade F. U. and Schlaak M., (1992) Pentoxifyllin - an inhibitor of tumor-necrosis-factor-alpha synthesis. Immun. Infekt. 20, 80-83.
192. Zabel P., Schade F. U. and Schlaak M. (1993a) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187, 447-463.
193. Zabel P., Greinert U., Entzian P. and Schlaak M. (1993b) Effects of pentoxifylline on circulating cytokines (TNF and IL-6) in severe pulmonary tuberculosis. In Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. (Edited by Fiers W. and Buurman WA) pp. 178-181. Karger, Basel.
194. Zabel P. and Schade F. U. (1994) Pentoxifylline and tumor necrosis factor-induced lung injury. Eur. Respir. J. 7, 1389-1391.